Human physiology

Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation

Retrieved on: 
Wednesday, July 14, 2021
Branches of biology, Animal physiology, Human physiology, Immunology, Inflammation

GLPG3970, the first product candidate from a broad portfolio of SIK inhibitor compounds, provides clinical data supporting the role of SIK inhibition in inflammation.

Key Points: 
  • GLPG3970, the first product candidate from a broad portfolio of SIK inhibitor compounds, provides clinical data supporting the role of SIK inhibition in inflammation.
  • Main objectives were to evaluate the safety and tolerability of GLPG3970 as well as early signs of biologic and clinical effect.
  • GLPG3970 is the first compound from Galapagos broad portfolio of novel molecules to provide clinical evidence for the potential role of SIK inhibition in inflammation.
  • Toledo is an extensive program with a novel target class, SIK, whose potential role in inflammation was discovered by Galapagos.

Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease

Retrieved on: 
Wednesday, July 14, 2021
Branches of biology, Immunology, Animal physiology, Human physiology, Inflammation

The CIHR grant entitled Therapeutic Targeting a Shared Inflammation Pathway in the Lungs and Kidneys was awarded to a research team at the University of Calgary led by Arch scientists Dr. Donna Senger and Dr. Daniel Muruve.

Key Points: 
  • The CIHR grant entitled Therapeutic Targeting a Shared Inflammation Pathway in the Lungs and Kidneys was awarded to a research team at the University of Calgary led by Arch scientists Dr. Donna Senger and Dr. Daniel Muruve.
  • The grant was one of five awarded in the CIHR Team Grant competition Preparation to Trial in Inflammation for Chronic Conditions.
  • The grant will also be used to determine the optimal design of clinical trials targeting DPEP-1 to prevent chronic disease in critically ill patients.
  • For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com .

CURAD® Launches Performance Series IRONMAN® Far Infrared Kinesiology Tape Designed for Training and Recovery

Retrieved on: 
Tuesday, June 8, 2021
Academic disciplines, Branches of biology, Ergonomics, Exercise physiology, Human physiology, Kinesiology, Motor control, Elastic therapeutic tape, Branches of science

NORTHFIELD, Ill., June 8, 2021 /PRNewswire/ -- CURAD , a leading provider of world-class consumer medical products, announces the launch of its Performance Series IRONMAN Far Infrared Kinesiology Tape fortified with Thrive Far Infrared technology.

Key Points: 
  • NORTHFIELD, Ill., June 8, 2021 /PRNewswire/ -- CURAD , a leading provider of world-class consumer medical products, announces the launch of its Performance Series IRONMAN Far Infrared Kinesiology Tape fortified with Thrive Far Infrared technology.
  • The addition of Thrive Far Infrared technology elevates the Performance Series IRONMAN Kinesiology Tape.
  • The Performance Series IRONMAN Far Infrared Kinesiology Tape is available in black and pink.
  • As the official medical supplier of IRONMAN, CURAD's Performance Series IRONMAN Far Infrared Kinesiology Tape can also be purchased online at the IRONMAN store .

Silo Pharma Announces Collaboration with University California San Francisco to study Psilocybin as an Anti-Inflammatory agent in Parkinson’s and Bipolar Patients

Retrieved on: 
Tuesday, June 8, 2021
Branches of biology, Clinical medicine, Medical specialties, Mood disorders, Animal physiology, Human physiology, Immunology, Inflammation, Anti-inflammatory, Chronic pain, Psilocybin, Bipolar disorder

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinsons, Bipolar disorder, and chronic back pain.

Key Points: 
  • This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinsons, Bipolar disorder, and chronic back pain.
  • Eric Weisblum, CEO of Silo Pharma commented Inflammation is a common mechanism across numerous physical diseases.
  • Inflammation has specifically been implicated in the pathophysiology of Parkinsons Disease,chronic pain, and bipolar disorder.
  • A better understanding of the anti-inflammatory effects of psilocybin has potential to allow for optimization and personalization of psilocybin treatment.

Xalud Therapeutics’ Lead Candidate, XT-150, Achieves Multiple Clinical Milestones in Pathologic Inflammation and Neuroimmunology Therapeutic Areas

Retrieved on: 
Thursday, May 20, 2021
Health, Genetics, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Branches of biology, Medical specialties, Biology, Immunology, Cytokines, Molecular biology, Animal physiology, Human physiology, Inflammation, Cytokine, Inflammatory cytokine, Plasmid, XT-150, Xalud Therapeutics, XT-150, XALUD THERAPEUTICS

XT-150 is a locally injectable, plasmid DNA gene therapy expressing IL-10v, a proprietary modified variant of the cytokine IL-10, to address pathologic inflammation and pain.

Key Points: 
  • XT-150 is a locally injectable, plasmid DNA gene therapy expressing IL-10v, a proprietary modified variant of the cytokine IL-10, to address pathologic inflammation and pain.
  • \xe2\x80\x9cThrough localized delivery of IL-10v, we believe XT-150 may have a large-scale impact in reducing inflammation at several somatic and neurologic targets.
  • XT-150 uses a non-integrating therapeutic plasmid DNA that enables local delivery of IL-10v directly to the site of inflammation.
  • IL-10 is a potent anti-inflammatory cytokine that plays a critical role in maintaining homeostasis and reducing inflammation.

Nephraegis Therapeutics Launches with Seed Financing to Develop Small Molecules to Prevent and Treat Acute Kidney Injury (AKI)

Retrieved on: 
Wednesday, May 12, 2021
Biotechnology, FDA, Managed care, Other Health, Health, Radiology, Pharmaceutical, Other Science, Research, Science, Clinical trials, Branches of biology, Animal physiology, Cell biology, Human physiology, Metabolic pathways, Cytochrome P450, Epoxyeicosatrienoic acid, Acute kidney injury, Aki, Kidney, NPH-022, Nephraegis Therapeutics, Inc., Xontogeny, LLC, NPH-022, NEPHRAEGIS THERAPEUTICS, INC., XONTOGENY, LLC

b"Nephraegis Therapeutics, Inc., a biopharmaceutical company developing NPH-022 to prevent and treat Acute Kidney Injury (AKI) today announced their launch with a seed investment from Xontogeny, LLC to advance their lead compound through critical preclinical work.\nThis press release features multimedia.

Key Points: 
  • b"Nephraegis Therapeutics, Inc., a biopharmaceutical company developing NPH-022 to prevent and treat Acute Kidney Injury (AKI) today announced their launch with a seed investment from Xontogeny, LLC to advance their lead compound through critical preclinical work.\nThis press release features multimedia.
  • Nephraegis' lead compound, NPH\xe2\x80\x91022, acts via the same pathway as endogenous epoxyeicosatrienoic acids (EETs), which regulate normal kidney function to respond to cellular stress events such as hypoxia or chemotoxicity.
  • This is especially important for our initial target, developing NPH-022 as a potentially promising new treatment to prevent AKI.\xe2\x80\x9d\nAKI is an abrupt loss of kidney function.
  • Nephraegis Therapeutics undertakes no obligation to update any forward-looking statements for any reason.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005296/en/\n"

ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirs

Retrieved on: 
Thursday, April 29, 2021
Research, Infectious diseases, Public relations, Investor relations, Clinical trials, Communications, AIDS, General Health, Health, Science, Other Science, Branches of biology, Medical specialties, Leukocytes, Human physiology, Immune system, Immunology, T cells, Lymphocytes, Natural killer cell, Agranulocyte, HIV, Peripheral blood mononuclear cell

Researchers will compare levels of HIV RNA and DNA in lymph node samples pre- and post-treatment and evaluate the therapy\xe2\x80\x99s effects on CD8+ T and natural killer (NK) immune cells.

Key Points: 
  • Researchers will compare levels of HIV RNA and DNA in lymph node samples pre- and post-treatment and evaluate the therapy\xe2\x80\x99s effects on CD8+ T and natural killer (NK) immune cells.
  • There was also evidence that Anktiva activated viral transcription and reduced the viral reservoir in peripheral blood mononuclear cells.
  • ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof.
  • ImmunityBio does not undertake any duty to update any forward-looking statement or other information in this press release, except to the extent required by law.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210429005421/en/\n'

Evommune to Present at the 20th Annual Needham Virtual Healthcare Conference

Retrieved on: 
Monday, April 12, 2021
Branches of biology, Immunology, Animal physiology, Human physiology, Inflammation, Calif

b'LOS ALTOS, Calif., April 12, 2021 /PRNewswire/ -- Evommune, Inc., a private R&D company and innovation engine inchronic inflammation, today announced that Luis Pea, president and chief executive officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021, at 11:15 a.m. PDT/2:15 p.m. EDT.\nTo access the live webcast and to watch the replay following the presentation, please click here .\nEvommune is a private R&D company and innovation engine in chronicinflammation.

Key Points: 
  • b'LOS ALTOS, Calif., April 12, 2021 /PRNewswire/ -- Evommune, Inc., a private R&D company and innovation engine inchronic inflammation, today announced that Luis Pea, president and chief executive officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021, at 11:15 a.m. PDT/2:15 p.m. EDT.\nTo access the live webcast and to watch the replay following the presentation, please click here .\nEvommune is a private R&D company and innovation engine in chronicinflammation.
  • The company is taking a tissue-based approach to advance insights and accelerate the development of transformative medicines in inflammatory diseases.
  • Evommune was founded in 2020 by a successful and experienced leadership team focused on building a robust pipeline of unique therapies that help patients with chronic inflammatory diseases.
  • The company is headquartered in Los Altos, Calif. For more information, please visit Evommune.com .\n'

OSE Immunotherapeutics Announces First Peer-Reviewed Publication in "Science Advances" on OSE-230, its Novel Monoclonal Antibody Agonist Therapy Triggering Resolution of Chronic Inflammation

Retrieved on: 
Tuesday, April 6, 2021
Branches of biology, Medical specialties, Biology, Cell biology, Immunology, Immune system, Phagocytes, Human physiology, Inflammation, Macrophage, Monoclonal antibody, Neutrophil

The preclinical results demonstrate that OSE-230 accelerates inflammation resolution and tissue hemostasis in severe inflammatory models.

Key Points: 
  • The preclinical results demonstrate that OSE-230 accelerates inflammation resolution and tissue hemostasis in severe inflammatory models.
  • Most importantly, OSE-230 triggers pro-resolutive actions resulting in the resolution of chronic inflammation in models where such recovery is deficient or missing.
  • This is the first peer-reviewed publication to describe an agonist monoclonal antibody, which triggers pro-resolutive mechanisms in macrophages and neutrophils in chronic inflammatory condition.
  • OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

Urban Skin Rx® Announces The Melanin Experts™

Retrieved on: 
Monday, March 29, 2021
Branches of biology, Biology, Human physiology, Human skin color, Hyperpigmentation, Rx, Skin care, Cosmetics

Led by Urban Skin Rx founder Rachel Roff and a team of in-house licensed aestheticians who specialize in skin of color, a.k.a.

Key Points: 
  • Led by Urban Skin Rx founder Rachel Roff and a team of in-house licensed aestheticians who specialize in skin of color, a.k.a.
  • "I founded Urban Skin Rx in 2010 to provide solutions to specific issues for women and men with melanin-rich skin.
  • As such, Urban Skin Rx channels will feature BIPOC tastemakers, skin specialists and competing brands, aiming a spotlight on and providing key insights from those outside the Urban Skin Rx network.
  • Urban Skin Rx products deliver blends of high-strength ingredients formulated to address the most common skincare concerns of women of color, including improving the appearance of hyperpigmentation and uneven skin tone.Urban Skin Rx products are sold at www.urbanskinrx.com and at over 5,000 retail locations across the U.S.
    For more information on Urban Skin Rx, please visit www.urbanskinrx.com .